Related Experiment Videos
Video-assisted thoracic surgery major pulmonary resections. Present experience
L Solaini1, F Prusciano, P Bagioni
1Thoracic Surgery Unit, Department of Surgery, S. Maria delle Croci Hospital, Viale Randi, 5, 48100, Ravenna, Italy. lsolaini@libero.it
Summary
Video-assisted thoracic surgery (VATS) is a safe and effective approach for major pulmonary resections, offering comparable long-term outcomes to open surgery for lung cancer patients.
Area of Science:
- Thoracic Surgery
- Minimally Invasive Surgery
- Surgical Oncology
Background:
- Video-assisted thoracic surgery (VATS) has emerged as an alternative to traditional thoracotomy for major pulmonary resections.
- Establishing the safety and efficacy of VATS for specific indications is crucial for patient outcomes.
Purpose of the Study:
- To review the institutional experience with VATS for major pulmonary resections.
- To evaluate the outcomes and complications associated with VATS in a diverse patient cohort.
Main Methods:
- A retrospective review of 125 patients undergoing VATS for major pulmonary resections between January 1993 and December 1999.
- Indications included benign lesions, solitary metastases, and Stage I non-small cell lung cancer (NSCLC) with lesions <4 cm.
- Procedures included lobectomies, bilobectomies, and pneumonectomy, with mediastinal node sampling/lymphadenectomy in NSCLC cases.
Main Results:
- VATS was successfully performed in 112 out of 125 patients (89.6%), with 13 conversions to open surgery (10.4%).
- Common procedures were lobectomies (108 cases). Postoperative complications occurred in 11.6% of patients, with one re-operation.
- For lung cancer patients, a 3-year survival rate of 85% was achieved, increasing to 90% for Stage I NSCLC.
Conclusions:
- VATS is a safe and effective method for pulmonary lobectomy, yielding results comparable to open surgery.
- Strict adherence to indications and timely conversion to thoracotomy when necessary are key to successful VATS procedures.
- VATS demonstrates promising long-term survival rates for early-stage lung cancer.